Read + Share
Molony DA, LeMaistre FI. In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney
disease, or CV or renal mortality. Ann Intern Med 2021 Feb 2. doi: 10.7326/ACPJ202102160.
PMID: 33524285
|
 |
|
Molony DA, LeMaistre FI. In CKD, dapagliflozin reduced a composite of eGFR decline, end-stage kidney
disease, or CV or renal mortality. Ann Intern Med 2021 Feb 2. doi: 10.7326/ACPJ202102160.
PMID: 33524285
|
|
|
|